---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-02-14T14:18:23.112839'
end_time: '2026-02-14T14:24:08.233362'
duration_seconds: 345.12
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: BACH2
  gene_symbol: BACH2
  uniprot_accession: Q9BYV9
  protein_description: 'RecName: Full=Transcription regulator protein BACH2; AltName:
    Full=BTB and CNC homolog 2;'
  gene_info: Name=BACH2;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the bZIP family. CNC subfamily. .
  protein_domains: BTB/POZ_dom. (IPR000210); bZIP. (IPR004827); bZIP_BACH. (IPR043321);
    bZIP_Maf. (IPR004826); bZIP_sf. (IPR046347)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 10
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9BYV9
- **Protein Description:** RecName: Full=Transcription regulator protein BACH2; AltName: Full=BTB and CNC homolog 2;
- **Gene Information:** Name=BACH2;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the bZIP family. CNC subfamily. .
- **Key Domains:** BTB/POZ_dom. (IPR000210); bZIP. (IPR004827); bZIP_BACH. (IPR043321); bZIP_Maf. (IPR004826); bZIP_sf. (IPR046347)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "BACH2" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'BACH2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **BACH2** (gene ID: BACH2, UniProt: Q9BYV9) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9BYV9
- **Protein Description:** RecName: Full=Transcription regulator protein BACH2; AltName: Full=BTB and CNC homolog 2;
- **Gene Information:** Name=BACH2;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the bZIP family. CNC subfamily. .
- **Key Domains:** BTB/POZ_dom. (IPR000210); bZIP. (IPR004827); bZIP_BACH. (IPR043321); bZIP_Maf. (IPR004826); bZIP_sf. (IPR046347)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "BACH2" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'BACH2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **BACH2** (gene ID: BACH2, UniProt: Q9BYV9) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan summary
- Verified the target as human BACH2 (UniProt Q9BYV9) and aligned domains/family with current literature. Searched 2023–2024 sources prioritizing authoritative reviews and recent mechanistic reports. Extracted evidence on molecular function, localization, pathways, immune roles, human genetics, and translational applications, focusing on precise mechanisms and human relevance. Created a tabular artifact summarizing key findings and sources.

Comprehensive research report on human BACH2 (UniProt: Q9BYV9)

Gene/protein verification and identity
BACH2 is the human BTB and CNC homologue 2, a cap’n’collar-type basic leucine zipper (CNC-bZIP) transcription factor with an N-terminal BTB/POZ domain and a C-terminal bZIP DNA-binding/dimerization domain. It forms homo- and heterodimers (notably with small MAF proteins MAFF/MAFG/MAFK) to bind MARE elements and primarily functions as a transcriptional repressor in lymphocytes. These features align with UniProt Q9BYV9 and the bZIP/CNC subfamily classification and BTB/POZ and bZIP domain architecture (Nature Reviews Immunology, 2023; Cells, 2024) (trujilloochoa2023theroleof pages 4-6, zwick2024bach2thefuture pages 1-3).

Key concepts and definitions with current understanding
- Core molecular function: BACH2 is a lineage-defining transcriptional regulator that represses effector differentiation programs by limiting AP-1 access to enhancers and by binding MARE motifs with small MAF partners. In T cells, it stabilizes regulatory programs and promotes stem-like/memory fates; in B cells, it supports germinal-center (GC) functions and class-switch recombination (Nature Reviews Immunology, 2023; Cells, 2024) (trujilloochoa2023theroleof pages 4-6, zwick2024bach2thefuture pages 3-5).
- Domain-functional map: BTB/POZ domain mediates protein–protein interactions and recruitment of corepressors; bZIP mediates DNA binding and dimerization with small MAFs. A C-terminal nuclear export sequence (NES) and nuclear localization determinants regulate nucleocytoplasmic shuttling (Cells, 2024) (zwick2024bach2thefuture pages 1-3, zwick2024bach2thefuture pages 3-5).

Recent developments and latest research (2023–2024 focus)
- Treg identity and stability: Authoritative review integrates recent mechanistic work showing BACH2 restrains effector Treg (eTreg) programs, enforces quiescence of resting Treg cells, and binds the FOXP3 promoter in TGF-β–induced human iTregs; downregulation allows effector/wound-healing genes (Nature Reviews Immunology, 2023; URL: https://doi.org/10.1038/s41577-023-00893-7, Jun 2023) (trujilloochoa2023theroleof pages 4-6, trujilloochoa2023theroleof pages 20-21).
- Post-translational and localization control: 2024 synthesis highlights that PI3K→AKT phosphorylation drives cytoplasmic accumulation, while oxidative stress and SENP3-mediated deSUMOylation favor nuclear retention; a key phosphosite controls localization and function. The review compiles data linking phosphorylation (including B-cell studies) and SUMOylation to nuclear export/import (Cells, 2024; URL: https://doi.org/10.3390/cells13110891, May 2024) (zwick2024bach2thefuture pages 3-5, zwick2024bach2thefuture pages 8-9, zwick2024bach2thefuture pages 12-13).
- CD8+ T cell state control: Recent summaries emphasize BACH2’s role in enforcing stem-like CD8+ states by restricting AP-1 access, shaping chromatin, and opposing premature terminal effector/exhaustion, with implications for chronic stimulation settings (Nature Reviews Immunology, 2023; Cells, 2024) (trujilloochoa2023theroleof pages 20-21, trujilloochoa2023theroleof pages 4-6).

Cellular localization and regulation
- Nucleocytoplasmic shuttling: BACH2 shuttles between nucleus and cytoplasm via a C-terminal NES and nuclear localization determinants. AKT-dependent phosphorylation promotes cytoplasmic localization; oxidative stress and deSUMOylation by SENP3 prevent nuclear export and increase nuclear BACH2 (Cells, 2024; Nature Reviews Immunology, 2023) (zwick2024bach2thefuture pages 3-5, trujilloochoa2023theroleof pages 20-21).
- Signal integration: Metabolic and signaling pathways (PKCβ→mTOR, PI3K→AKT) modulate BACH2 activity and localization; these pathways tune effector restraint versus differentiation in lymphocytes (Cells, 2024) (zwick2024bach2thefuture pages 8-9, zwick2024bach2thefuture pages 3-5).

Primary biological roles and precise functions
- B cells (primary GC functions): BACH2 is required for efficient class-switch recombination (CSR) and for maintaining GC programs while restraining PRDM1/Blimp-1-driven plasma-cell differentiation, thereby promoting memory B cell fate. Mechanistically, it binds and represses effector/PC genes and competes with AP-1 factors on target enhancers (Nature Reviews Immunology, 2023; URL above) (trujilloochoa2023theroleof pages 4-6).
- CD4+ Treg lineage and function: BACH2 represses broad effector transcriptional programs to maintain Treg identity and homeostasis; loss impairs TGF-β–induced iTreg generation and leads to systemic autoimmunity in mouse models. In human iTregs (umbilical cord blood), BACH2 binds FOXP3 promoter and supports stability (Nature Reviews Immunology, 2023; Cells, 2024) (trujilloochoa2023theroleof pages 4-6, zwick2024bach2thefuture pages 1-3).
- CD8+ T cell differentiation: BACH2 promotes stem-like/memory differentiation, restricts terminal effector differentiation, and shapes enhancer access by AP-1, preserving functionality during persistent antigen exposure (Nature Reviews Immunology, 2023; Cells, 2024) (trujilloochoa2023theroleof pages 20-21, trujilloochoa2023theroleof pages 4-6).

Pathways and molecular interactors
- Dimerization partners and DNA elements: small MAFs (MAFF/MAFG/MAFK) are canonical partners; BACH2 binds MARE motifs and competes with AP-1 (e.g., JUND) at enhancers (Nature Reviews Immunology, 2023) (trujilloochoa2023theroleof pages 4-6).
- Transcriptional network in lymphocytes: Interacts functionally with IRF4 and PRDM1/Blimp-1 in B-cell programs; restrains genes such as Jun, Prdm1, Gata3, Irf4, Nfil3, Ahr, Gzmb in T cells to hold effector programs in check (Nature Reviews Immunology, 2023) (trujilloochoa2023theroleof pages 4-6).
- Signaling crosstalk: PTEN–AKT axis and mTOR/PKCβ pathways modulate BACH2 activity and nuclear residence; oxidative stress and SUMO/SENP3 rewire localization and iTreg stability (Cells, 2024) (zwick2024bach2thefuture pages 8-9, zwick2024bach2thefuture pages 3-5).

Genetic evidence in human disease
- Mendelian: BACH2 haploinsufficiency (BACH2-related immunodeficiency and autoimmunity, BRIDA) causes immune dysregulation with autoimmunity and features of immunodeficiency. Reviews collate human coding variant reports and super-enhancer dysregulation at the BACH2 locus (Cells, 2024; Nature Reviews Immunology, 2023) (zwick2024bach2thefuture pages 12-13, trujilloochoa2023theroleof pages 4-6).
- Common variant associations: GWAS/meta-analyses consistently implicate BACH2 in autoimmune susceptibility, including type 1 diabetes, Crohn’s disease, celiac disease, rheumatoid arthritis, multiple sclerosis, asthma, vitiligo, and autoimmune thyroid disease. Specific SLE-associated variant rs597325 is highlighted in compilations (Nature Reviews Immunology, 2023; Cells, 2024) (trujilloochoa2023theroleof pages 4-6, zwick2024bach2thefuture pages 12-13).

Current applications and real-world implementations
- iTreg therapy optimization: Reviews propose stabilizing BACH2 during human iTreg manufacturing to overcome instability and enhance suppressive potency; mesenchymal stromal cell co-culture and redox/SUMO pathway modulation are discussed as strategies to maintain nuclear BACH2 and FOXP3 stability (Cells, 2024; URL above) (zwick2024bach2thefuture pages 8-9, zwick2024bach2thefuture pages 1-3).
- T cell therapy engineering: Conceptual and preclinical frameworks position BACH2 as a “memory transcription factor” to be dosed/tuned to preserve stem-like states and counter exhaustion in engineered T cells (e.g., CAR-T) under chronic antigen exposure, while acknowledging safety/lineage control considerations (Negrin thesis 2026; synthesis in 2024 review) (negrin2026enhancingtcella pages 34-37, trujilloochoa2023theroleof pages 20-21).

Expert opinions and analysis from authoritative sources
- Nature Reviews Immunology (2023) synthesizes primary evidence to position BACH2 as a central regulator of Treg identity, a gatekeeper of quiescence, and a broad repressor of effector programs across T cells, with extensive GWAS support for autoimmunity. It emphasizes AP-1 competition, FOXP3 promoter binding in iTregs, and chromatin-level control in CD8+ T cell fates (Nature Reviews Immunology, 2023) (trujilloochoa2023theroleof pages 4-6, trujilloochoa2023theroleof pages 20-21).
- The 2024 Cells review argues for BACH2 as a master regulator whose activity is exquisitely sensitive to activation and metabolic state, highlighting PTM control (phosphorylation, SUMO) and proposing actionable levers to enhance iTreg therapy. It compiles human genetic links including BRIDA and broad autoimmune associations (Cells, 2024) (zwick2024bach2thefuture pages 3-5, zwick2024bach2thefuture pages 12-13, zwick2024bach2thefuture pages 8-9, zwick2024bach2thefuture pages 1-3).

Relevant statistics and data from recent studies
- Human genetics breadth: Compilations in 2023–2024 reviews list multiple autoimmune GWAS signals at BACH2 (e.g., T1D, Crohn’s, MS, celiac, RA, vitiligo, AITD), indicating pleiotropic autoimmunity risk mediated by BACH2 locus variation; specific SLE-associated SNP rs597325 is cited (Nature Reviews Immunology, 2023; Cells, 2024) (trujilloochoa2023theroleof pages 4-6, zwick2024bach2thefuture pages 12-13). While these sources aggregate findings, they do not provide single-study cohort n/effect sizes within the cited pages; they nevertheless indicate convergent multi-disease evidence.
- Mechanistic localization control: The 2024 synthesis specifies that PI3K–AKT phosphorylation biases cytoplasmic localization, while oxidative stress and SENP3-mediated deSUMOylation block nuclear export and enhance nuclear accumulation—mechanistically supporting intervention points for cell-therapy manufacturing (Cells, 2024) (zwick2024bach2thefuture pages 3-5, zwick2024bach2thefuture pages 8-9).

Limitations and scope
- Most mechanistic precision for enhancer competition, chromatin regulation, and T cell lineage control integrates mouse and human evidence; the cited 2023–2024 reviews clearly demarcate human relevance where available. Where quantitative GWAS effect sizes or cohort counts are not enumerated in the review excerpts, we report convergent disease links rather than specific statistics (trujilloochoa2023theroleof pages 4-6, zwick2024bach2thefuture pages 12-13).

Embedded summary artifact
| Aspect | Summary & sources |
|---|---|
| Identity / Domains | • BTB/POZ N‑terminal domain; C‑terminal basic‑region leucine‑zipper (bZIP); heterodimerizes with small MAF proteins; lymphoid‑enriched, ≈92 kDa. Sources: Zwick et al. 2024 https://doi.org/10.3390/cells13110891; Trujillo‑Ochoa et al. 2023 https://doi.org/10.1038/s41577-023-00893-7 (zwick2024bach2thefuture pages 3-5, trujilloochoa2023theroleof pages 20-21) |
| Molecular mechanism | • Transcriptional repressor at MARE motifs; limits AP‑1 access to enhancers (competitive repression). • Regulated by PTMs: phosphorylation (PI3K→AKT) and SUMO/SENP3 control nuclear export/retention and activity. Sources: Zwick et al. 2024 https://doi.org/10.3390/cells13110891; Trujillo‑Ochoa et al. 2023 https://doi.org/10.1038/s41577-023-00893-7 (zwick2024bach2thefuture pages 3-5, trujilloochoa2023theroleof pages 20-21) |
| Primary immune roles | • B cells: enforces germinal‑center programs, restrains premature plasma‑cell differentiation, required for class‑switch recombination and memory B cell fate. • T cells: stabilizes FOXP3+ iTreg phenotype and represses effector programs; in CD8+ T cells promotes stem‑like/memory states and limits terminal effector/exhaustion. Sources: Trujillo‑Ochoa et al. 2023 https://doi.org/10.1038/s41577-023-00893-7; Zwick et al. 2024 https://doi.org/10.3390/cells13110891 (trujilloochoa2023theroleof pages 20-21, zwick2024bach2thefuture pages 3-5) |
| Subcellular localization & regulation | • Nucleus↔cytoplasm shuttling via NES/NLS; phosphorylation (PI3K→AKT) favors cytoplasmic localization. • Oxidative stress and SUMO/SENP3‑mediated regulation promote nuclear retention and functional switching. Sources: Zwick et al. 2024 https://doi.org/10.3390/cells13110891; Trujillo‑Ochoa et al. 2023 https://doi.org/10.1038/s41577-023-00893-7 (zwick2024bach2thefuture pages 3-5, trujilloochoa2023theroleof pages 20-21) |
| Key pathways & interactors | • Partners/targets: small MAFs (MAFF/MAFG/MAFK), IRF4, PRDM1/Blimp‑1; competes with AP‑1 factors at enhancers. • Linked signaling: PTEN→AKT (metabolic control) and mTOR/PKC axes affecting BACH2 activity. Sources: Trujillo‑Ochoa et al. 2023 https://doi.org/10.1038/s41577-023-00893-7; Zwick et al. 2024 https://doi.org/10.3390/cells13110891 (trujilloochoa2023theroleof pages 20-21, zwick2024bach2thefuture pages 3-5) |
| Human genetics & disease links | • Mendelian: heterozygous BACH2 loss (haploinsufficiency / BRIDA) → immune dysregulation with autoimmunity and immunodeficiency. • Common‑variant: GWAS associations across autoimmune diseases (T1D, Crohn's, MS, vitiligo, autoimmune thyroid disease, etc.). Sources: Zwick et al. 2024 https://doi.org/10.3390/cells13110891; Trujillo‑Ochoa et al. 2023 https://doi.org/10.1038/s41577-023-00893-7 (zwick2024bach2thefuture pages 3-5, trujilloochoa2023theroleof pages 20-21) |
| Translational / clinical applications | • iTreg cell therapy: increasing/stabilizing BACH2 proposed to improve iTreg stability and suppressive function during manufacture. • T cell engineering/CAR‑T: dosage/timing tuning of BACH2 to preserve memory/stem‑like states and improve persistence in chronic antigen settings (preclinical/strategic proposals). Sources: Zwick et al. 2024 https://doi.org/10.3390/cells13110891; Negrin 2026 discussion (T‑cell dosing concept) (zwick2024bach2thefuture pages 3-5, negrin2026enhancingtcella pages 34-37) |


*Table: Concise, evidence‑linked table summarizing human BACH2 (UniProt Q9BYV9) covering domains, mechanism, immune roles, localization, interactors, genetic links, and translational applications with source URLs and evidence IDs.*

Conclusion
Human BACH2 (Q9BYV9) is a CNC-bZIP transcriptional regulator with BTB/POZ and bZIP domains that dimerizes with small MAFs to bind MAREs and broadly represses AP‑1–driven effector programs. It integrates metabolic and signaling inputs (PI3K–AKT, mTOR, oxidative/SUMO) via PTMs to control nuclear localization and activity. In B cells, it is required for GC integrity and CSR while restraining plasma-cell differentiation; in T cells, it stabilizes FOXP3+ Tregs and enforces stem-like/memory CD8+ states that resist terminal exhaustion. Human genetics links haploinsufficiency (BRIDA) and common variants at BACH2 to multiple autoimmune diseases. Recent 2023–2024 analyses converge on translational strategies to modulate BACH2—particularly to stabilize iTregs and tune engineered T cells under chronic antigen—to enhance clinical efficacy while preserving safety (trujilloochoa2023theroleof pages 4-6, trujilloochoa2023theroleof pages 20-21, zwick2024bach2thefuture pages 3-5, zwick2024bach2thefuture pages 8-9, zwick2024bach2thefuture pages 12-13, zwick2024bach2thefuture pages 1-3, negrin2026enhancingtcella pages 34-37, negrin2026enhancingtcell pages 34-37).

References

1. (trujilloochoa2023theroleof pages 4-6): Jorge L. Trujillo-Ochoa, Majid Kazemian, and Behdad Afzali. The role of transcription factors in shaping regulatory t cell identity. Nature Reviews Immunology, 23:842-856, Jun 2023. URL: https://doi.org/10.1038/s41577-023-00893-7, doi:10.1038/s41577-023-00893-7. This article has 111 citations and is from a highest quality peer-reviewed journal.

2. (zwick2024bach2thefuture pages 1-3): Daniel Zwick, Mai Tram Vo, Young Jun Shim, Helena Reijonen, and Jeong-su Do. Bach2: the future of induced t-regulatory cell therapies. Cells, 13:891, May 2024. URL: https://doi.org/10.3390/cells13110891, doi:10.3390/cells13110891. This article has 8 citations and is from a poor quality or predatory journal.

3. (zwick2024bach2thefuture pages 3-5): Daniel Zwick, Mai Tram Vo, Young Jun Shim, Helena Reijonen, and Jeong-su Do. Bach2: the future of induced t-regulatory cell therapies. Cells, 13:891, May 2024. URL: https://doi.org/10.3390/cells13110891, doi:10.3390/cells13110891. This article has 8 citations and is from a poor quality or predatory journal.

4. (trujilloochoa2023theroleof pages 20-21): Jorge L. Trujillo-Ochoa, Majid Kazemian, and Behdad Afzali. The role of transcription factors in shaping regulatory t cell identity. Nature Reviews Immunology, 23:842-856, Jun 2023. URL: https://doi.org/10.1038/s41577-023-00893-7, doi:10.1038/s41577-023-00893-7. This article has 111 citations and is from a highest quality peer-reviewed journal.

5. (zwick2024bach2thefuture pages 8-9): Daniel Zwick, Mai Tram Vo, Young Jun Shim, Helena Reijonen, and Jeong-su Do. Bach2: the future of induced t-regulatory cell therapies. Cells, 13:891, May 2024. URL: https://doi.org/10.3390/cells13110891, doi:10.3390/cells13110891. This article has 8 citations and is from a poor quality or predatory journal.

6. (zwick2024bach2thefuture pages 12-13): Daniel Zwick, Mai Tram Vo, Young Jun Shim, Helena Reijonen, and Jeong-su Do. Bach2: the future of induced t-regulatory cell therapies. Cells, 13:891, May 2024. URL: https://doi.org/10.3390/cells13110891, doi:10.3390/cells13110891. This article has 8 citations and is from a poor quality or predatory journal.

7. (negrin2026enhancingtcella pages 34-37): A Conti Negrin. Enhancing t cell immunotherapy through dosing of memory transcription factors. Unknown journal, 2026.

8. (negrin2026enhancingtcell pages 34-37): A Conti Negrin. Enhancing t cell immunotherapy through dosing of memory transcription factors. Unknown journal, 2026.

## Citations

1. trujilloochoa2023theroleof pages 4-6
2. trujilloochoa2023theroleof pages 20-21
3. negrin2026enhancingtcella pages 34-37
4. negrin2026enhancingtcell pages 34-37
5. https://doi.org/10.1038/s41577-023-00893-7,
6. https://doi.org/10.3390/cells13110891,
7. https://doi.org/10.3390/cells13110891;
8. https://doi.org/10.1038/s41577-023-00893-7
9. https://doi.org/10.1038/s41577-023-00893-7;
10. https://doi.org/10.3390/cells13110891